Status: Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Participants needed: 56
Trial details
Phase: Phase 2Age: 18-68Biological sex: AllType: InterventionalSponsor: Maze TherapeuticsUpdated: Apr 17, 2026Locations: 81
Eligibility criteria
APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 [+1]
Organ or bone marrow transplantation [+4]